Literature DB >> 15517914

E2F-1 transcription factor immunoexpression is inversely associated with tumor growth in colon adenocarcinomas.

John Bramis1, Panayotis Zacharatos, Ioannis Papaconstantinou, Athanassios Kotsinas, Frangisca Sigala, Dimitrios P Korkolis, Nikolaos Nikiteas, Anastasia Pazaiti, Christos Kittas, Elias Bastounis, Vassilis G Gorgoulis.   

Abstract

E2F-1 is an intriguing transcription factor that accumulates the integrated signal of the G1-S transition regulators. Its role in cell fate, as depicted from in vivo models and a few studies on human tissues, is a matter of debate, since it confers a tissue-specific oncogenic or tumor suppressor behavior. In the present work, in an attempt to shed light on the role of E2F-1 in colon cancer, we examined E2F-1 expression in a series of 45 colon carcinomas and we further correlated it with tumor kinetics. E2F-1 expression and proliferation were evaluated by immunohistochemistry as the percentage of E2F-1 (E2F-1 index: EI) and Ki-67 (Proliferation index: PI)-positive cells, respectively; whereas apoptosis was estimated as the percentage of positive, by TUNEL assay, cells (Apoptotic index: AI). The relationship between E2F-1 expression and tumor kinetics was assessed by microscopical evaluation in semi-serial tissue sections and statistical analysis. Our results demonstrated that E2F-1 expression was inversely correlated with tumor growth (GI=PI/AI) (p=0.002). Specifically, the histological observations showed that E2F-1 was expressed in lesions with high apoptotic incidence and low proliferation. These results also supported the statistical findings showing that EI was inversely correlated with PI (p < 0.001) and positively associated with AI (p = 0.013). In conclusion, we suggest a tumor-suppressive behavior of E2F-1 in colon carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517914

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Prognostic value of E2F1 in rectal cancer.

Authors:  Hasan Uzer; Hızır Akyıldız; Erdoğan Sözüer; Alper Akcan; Bahadır Öz
Journal:  Turk J Surg       Date:  2017-09-01

2.  miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes.

Authors:  Joel R Pekow; Urszula Dougherty; Reba Mustafi; Hongyan Zhu; Masha Kocherginsky; David T Rubin; Stephen B Hanauer; John Hart; Eugene B Chang; Alessandro Fichera; Loren J Joseph; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2011-05-06       Impact factor: 5.325

Review 3.  E2F transcription factors and digestive system malignancies: how much do we know?

Authors:  Athanasios Xanthoulis; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

4.  Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon.

Authors:  Joel Pekow; Katherine Meckel; Urszula Dougherty; Fatma Butun; Reba Mustafi; John Lim; Charis Crofton; Xindi Chen; Loren Joseph; Marc Bissonnette
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-12-04       Impact factor: 4.052

5.  E2F1 expression is deregulated and plays an oncogenic role in sporadic Burkitt's lymphoma.

Authors:  Irene Molina-Privado; María Rodríguez-Martínez; Patricia Rebollo; Daniel Martín-Pérez; María-Jesús Artiga; Javier Menárguez; Erik K Flemington; Miguel A Piris; Miguel R Campanero
Journal:  Cancer Res       Date:  2009-05-01       Impact factor: 12.701

Review 6.  Emerging roles of E2Fs in cancer: an exit from cell cycle control.

Authors:  Hui-Zi Chen; Shih-Yin Tsai; Gustavo Leone
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

7.  Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model.

Authors:  Yang Yan; Yingxin Xu; Yunshan Zhao; Li Li; Peiming Sun; Hailiang Liu; Qinghao Fan; Kai Liang; Wentao Liang; Huiwei Sun; Xiaohui Du; Rong Li
Journal:  Tumour Biol       Date:  2013-09-14

8.  Targeting phospholipase D1 attenuates intestinal tumorigenesis by controlling β-catenin signaling in cancer-initiating cells.

Authors:  Dong Woo Kang; Chi Yeol Choi; Yong-Hee Cho; Huasong Tian; Gilbert Di Paolo; Kang-Yell Choi; Do Sik Min
Journal:  J Exp Med       Date:  2015-06-29       Impact factor: 14.307

9.  Age-specific differences in oncogenic pathway deregulation seen in human breast tumors.

Authors:  Carey K Anders; Chaitanya R Acharya; David S Hsu; Gloria Broadwater; Katherine Garman; John A Foekens; Yi Zhang; Yixin Wang; Kelly Marcom; Jeffrey R Marks; Sayan Mukherjee; Joseph R Nevins; Kimberly L Blackwell; Anil Potti
Journal:  PLoS One       Date:  2008-01-02       Impact factor: 3.240

Review 10.  Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?

Authors:  P Meng; R Ghosh
Journal:  Cell Death Dis       Date:  2014-08-07       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.